Prediction of Hepatocellular Carcinoma and Liver-related Events in Anti-hepatitis D Virus-positive Individuals
Year: 2024
Type: article
Study design: Observational Study
Abstract: BACKGROUND & AIMS: Chronic hepatitis D (CHD) is the most severe form of chronic viral hepatitis, with a high risk of developing hepatocellular carcinoma (HCC) and liver-related mortality. Risk stratification is needed to guide HCC surveillance strategies and to prioritize treatment with antiviral agents. METHODS: We conducted a multicenter retrospective cohort of anti-hepatitis D virus (HDV)-positive individuals managed at sites in the Netherlands and the United Kingdom. We studied the 5-year cumulative incidences of HCC and liver-related events (first of HCC, liver transplantation, and liver-related mortality), in the overall cohort and among relevant subgroups. RESULTS: We analyzed 269 anti-HDV-positive individuals with a median follow-up of 4.3 years in which 47 first events occurred. The 5-year cumulative incidences of HCC and liver-related events were 3.8% and 15.6% in the overall cohort. The 5-year cumulative incidence of HCC and liver-related events for individuals without cirrhosis was 0% and 0.9% compared with 12% and 41.3% for individuals with cirrhosis (P < .001). The 5-year cumulative incidence of HCC and liver-related events was 0% and 2.1% among individuals with low PAGE-B scores, compared to 3.2% and 21.1% with intermediate and 25.4% and 45.5% with high-risk scores (P < .001). We found comparable results for the Fibrosis-4 score. Findings were consistent regardless of cirrhosis or detectable HDV RNA (P < .001). CONCLUSIONS: Anti-HDV-positive individuals are at high risk of adverse liver-related outcomes. The incidence of HCC was negligible among individuals without cirrhosis and among individuals with low baseline PAGE-B and/or Fibrosis-4 scores. Therefore, these scores can be used to guide HCC surveillance strategies and potentially also for treatment prioritization.
Authors: Lesley A. Patmore, Michelle Spaan, Kosh Agarwal, Özgür M. Koc, Hans Blokzijl, Samantha Brouwer, Hanneke van Soest, Astrid G.W. van Hulzen, Harry L.A. Janssen, A.J. Jolanda Lammers, Louis Jansen, Mark Claassen, Robert A. de Man, R. Bart Takkenberg, Remco van Dijk, Dirk Posthouwer, Jurriën G.P. Reijnders, Ivana Carey, Milan J. Sonneveld
Institutions: Erasmus MC, King's College Hospital, Maastricht University Medical Centre, Maastricht University, University Medical Center Groningen, University of Groningen, Haga Hospital, Medisch Centrum Haaglanden, Stichting Haaglanden Medisch Centrum, Isala, OLVG, Rijnstate Hospital, Amsterdam UMC Location University of Amsterdam, Amsterdam University Medical Centers, Leiden University Medical Center
Language: English
Topic: Hepatitis B Virus Studies
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,050
Funder: Gilead Sciences
OpenAlex ID: W4403280133
